Search
Search Funnelback University
- Refined by:
- Date: 2022
51 -
100 of
183
search results for news |u:www.enterprise.cam.ac.uk
Fully-matching results
-
The journey of a University idea – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/for-the-university/develop-a-commercial-opportunity/the-journey-of-a-university-idea/10 May 2022: Here are some ideas:. Performance/applications data. Prototype development, scale-up of process, develop new applications. ... parties. Example of a benefit statement. We can help primary school teachers teach children to speak a new language more -
£1.5m seed funding for Cambridge spin-out iKVA – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/university-of-cambridge-spin-out-ikva-secures-1-5m-seed-funding/2 Feb 2022: £1.5m investment via Crowdcube and Cambridge Enterprise creates new jobs and further development of the tech. -
KARPAS 707H Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-707h-human-myeloma-cell-line/9 May 2022: KARPAS 707H Human myeloma cell line suitable for the generation of stable human hybridomas for the creation of fully human monoclonal antibodies. -
Nyobolt: Supercharging the electric revolution – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/nyobolt-supercharging-the-electric-revolution/11 Apr 2022: A new class of battery technology. Nyobolt’s team of experts has pioneered a new class of battery technology that achieves record-breaking ultra-fast charging. -
Cambridge Enterprise 1 Cambridge Enterprise: Q&A w ith Joao ...
https://www.enterprise.cam.ac.uk/wp-content/uploads/2022/11/2022.11.23_AHSS-QA-Joao-Costa_Web-1.pdf23 Nov 2022: a foothold on the ground, who could go in and do preliminary consultations to grasp whether the communities could be interested or not in trying something new. -
Cambridge recognised for its leadership in knowledge exchange –…
https://www.enterprise.cam.ac.uk/news/cambridge-recognised-for-its-leadership-in-knowledge-exchange/27 Sep 2022: Early stage innovations are licensed to existing companies for development or spun out as new companies. ... Among these were three companies developing new technologies focused on reducing carbon emissions—and Carbon Re. -
KARPAS 1272 Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-1272-human-myeloma-cell-line/9 May 2022: KARPAS 1272 Human Myeloma cell line, useful in oncology research, developed at the University of Cambridge. -
Sustainability, investment and the Carbon Challenge – Cambridge…
https://www.enterprise.cam.ac.uk/video/sustainability-investment-and-the-carbon-challenge/12 Oct 2022: Chris Gibbs shares his perspectives on the importance of sustainability, investing in sustainability businesses and building entrepreneurial mindsets through the Carbon Challenge. -
Impact Insight video case study: Kalamna toolkit – Cambridge…
https://www.enterprise.cam.ac.uk/case-studies/impact-insight-video-case-study-kalamna-toolkit/15 Mar 2022: Impact Insight video case study: Kalamna toolkit. The third in our new series of Impact Insight videos focuses on the licensing of the Kalamna toolkit for learning Arabic. ... Dr Khalil has spent her career researching how young Arabic learners can be -
TenU receives £4 million to boost research commercialisation –…
https://www.enterprise.cam.ac.uk/news/tenu-receives-4-million-to-boost-research-commercialisation/18 Aug 2022: with the potential to provide tens of thousands of new jobs over the next few years. -
KARPAS 241 Human Monoblastic cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-241-human-monoblastic-cell-line/9 May 2022: KARPAS 241 Human Monoblastic cell line useful in oncology research, developed at the University of Cambridge. -
Ceres Agri-Tech Partnership – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/ceres-a-rich-harvest-of-agri-tech-projects/11 Apr 2022: Over the past year, the team has identified and reviewed 55 new opportunities and presented 13 to the Ceres Investment Committee. -
COBRAS Concrete Bridge Assessment Program – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/reagents/cobras-concrete-bridge-assessment-program/9 May 2022: COBRAS Concrete Bridge Assessment Program is a yield-line analysis software for assessing the ultimate load capacity of concrete structures. -
Cambridge joins $72.5m round launching mitochondrial therapies…
https://www.enterprise.cam.ac.uk/news/cambridge-joins-72-5m-round-launching-mitochondrial-therapies-pioneer-pretzel/19 Sep 2022: We are excited to pioneer a new era in the treatment of diseases related to mitochondrial dysfunction. ... The expertise we have assembled and the platform technologies we have created will allow new inroads into treating both rare genetic diseases as -
BOADICEA: Calculating the risk of breast cancer – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/boadicea-calculating-the-risk-of-breast-cancer/11 Apr 2022: New Zealand Family Cancer Services. BOADICEA being incorporated within BRRISK helps time-poor GP’s to stratify patients according to risk. ... Oncoplastic Breast Surgeon, Auckland, New Zealand. Pause. Play. If you would like more information on BOADICEA -
Brief Early Skills & Support Index (BESSI) – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/reagents/brief-early-skills-support-index-bessi/9 May 2022: Questionnaire developed at the University of Cambridge and validated for use with reception- and nursery-aged children. -
Finalists announced in 2022 Chris Abell Postdoc Business Plan…
https://www.enterprise.cam.ac.uk/news/finalists-announced-in-2022-chris-abell-postdoc-business-plan-competition/4 Oct 2022: The finalists’ pitches will be judged on a number of criteria, including each business’s competitive position, the potential for new business creation, and each team’s collective skill set. -
Case study: Futures We Want – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/consultancy-services-determining-the-futures-we-want/11 Apr 2022: Evidence included scientific papers, government reports, and local news articles. The close collaboration with local expert teams throughout the process brought great depth of knowledge, and ensured that visions remained focused -
Human CD59 monoclonal antibody YTH 53.1
https://www.enterprise.cam.ac.uk/reagents/human-cd59-monoclonal-antibody-yth-53-1/9 May 2022: Hybridoma cell line producing YTH 53.1 antibodies raised against human CD59 which are rat monoclonal antibodies of the IgG2b isotype. -
Sparxell wins the 2022 Chris Abell Postdoc Business Plan Competition…
https://www.enterprise.cam.ac.uk/news/sparxell-wins-the-2022-chris-abell-postdoc-business-plan-competition/11 Nov 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. 11 November 2022. Sparxell wins the 2022 Chris Abell Postdoc Business Plan Competition. Share:. Sparxell has won the Chris Abell Postdoc Business Plan Competition 2022, securing the £20 -
Human CD7 monoclonal antibody YTH 30.15
https://www.enterprise.cam.ac.uk/reagents/human-cd7-monoclonal-antibody-yth-30-15/9 May 2022: Hybridoma cell line producing YTH 30.15 antibodies raised against human CD7 which are rat monoclonal antibodies of the IgG2b isotype. -
HappyShield: A simple, elegant solution to PPE scarcity – Cambridge…
https://www.enterprise.cam.ac.uk/case-studies/happyshield-a-simple-elegant-solution-to-ppe-scarcity/11 Apr 2022: HappyShield provides a barrier from splashes and sprays of infected bodily fluids and can be cleaned and reused indefinitely. -
Semi-finalists announced in 2022 Chris Abell Postdoc Business Plan…
https://www.enterprise.cam.ac.uk/news/semi-finalists-announced-in-2022-chris-abell-postdoc-business-plan-competition/17 Aug 2022: In addition, applicants will benefit from even more support with our new summer programme, which offers an additional series of activities through a blend of round table discussions, one-to-one -
Rat CD45 monoclonal antibody YTH 24.5
https://www.enterprise.cam.ac.uk/reagents/human-cd45-monoclonal-antibody-yth-24-5/9 May 2022: Hybridoma cell line producing YTH 24.5 antibodies raised against human CD45 which are rat monoclonal antibodies of the IgG2b isotype. -
Human CD11a monoclonal antibody YTH 81.5
https://www.enterprise.cam.ac.uk/reagents/human-cd11a-monoclonal-antibody-yth-81-5/9 May 2022: Hybridoma cell line producing YTH 81.5 antibodies raised against human CD11a which are rat monoclonal antibodies of the IgG2a isotype. -
Apollo Therapeutics: Pioneering collaboration launches its next phase …
https://www.enterprise.cam.ac.uk/case-studies/apollo-therapeutics-pioneering-collaboration-launches-its-next-phase/11 Apr 2022: so-called Valley of Death, the interval when promising new research can wither and die for lack of funding. ... Next steps. Apollo is now advancing into clinical development as well as identifying new programmes. -
Human CD16 monoclonal antibody YFC 120.5
https://www.enterprise.cam.ac.uk/reagents/human-cd16-monoclonal-antibody-yfc-120-5/9 May 2022: Hybridoma cell line producing YFC 120.5 antibodies raised against human CD16 which are rat monoclonal antibodies of the IgG2b isotype. -
Cambridge spin-out raises $6m seed round for transformative…
https://www.enterprise.cam.ac.uk/news/cambridge-spin-out-raises-6m-seed-round-for-transformative-regulatory-data-structures/12 Apr 2022: University of Cambridge spin-out RegGenome announces the completion of a $6 million seed funding round. -
Knowledge exchange in southern Africa – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/knowledge-exchange-teaching-and-learning-in-southern-africa/11 Apr 2022: We ran a knowledge exchange programme on research commercialisation for three southern African universities in 2019. -
FcgRlla 131R receptor expressing cell line
https://www.enterprise.cam.ac.uk/reagents/fcgrlla-131r-receptor-expressing-cell-line/9 May 2022: CHO cells transfected to express human FcgRlla allotype 131R as a transmembrane protein with its native intracellular domain. -
Cambridge Enterprise leads £1m investment in cancer care management…
https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-leads-1m-investment-in-cancer-care-management-device-start-up/28 Apr 2022: and Macmillan Cancer Support, in order to define a new clinical pathway for treating suspected neutropenic sepsis, and to ensure people living with disease continue to be at the heart of -
Cambridge GaN Devices case study – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/cambridge-gan-devices-reshaping-power-electronics-for-a-greener-future/11 Apr 2022: investment. Less than five years later, we again released news about the company. ... This time, however, the news was the completion of a $9.5 million Series A funding round. -
FcgRlla 131H receptor expressing cell line
https://www.enterprise.cam.ac.uk/reagents/fcgrlla-131h-receptor-expressing-cell-line/9 May 2022: CHO cells transfected to express human FcgRlla allotype 131H as a transmembrane protein with its native intracellular domain. -
Cambridge spin-out secures $3.4m to invent the way humanity interacts …
https://www.enterprise.cam.ac.uk/news/cambridge-spin-out-secures-3-4m-to-invent-the-way-humanity-interacts-with-a-i/23 Mar 2022: Insights from Tenyks help engineers accelerate their development lifecycle, so they spend less time onboarding new users, reducing customer acquisition costs, and boosting the accuracy of AI. ... Moreover, future new deployments can be onboarded in half -
Rat CD45 monoclonal antibody YTH 54.12
https://www.enterprise.cam.ac.uk/reagents/mouse-cd45-monoclonal-antibody-yth-54-12/9 May 2022: Hybridoma cell line producing YTH 54.12 antibodies raised against human CD45 which are rat monoclonal antibodies of the IgG2b isotype. -
Cambridge Enterprise co-leads £2.4m investment in spin-out developing …
https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-co-leads-2-4m-investment-in-spin-out-developing-adc-cancer-therapeutics/14 Jun 2022: Share:. Spirea Limited, a University of Cambridge spin-out company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has secured funding of £2.4 million. ... We welcome our new investors and thank our existing investors -
FcgRllb 131R receptor expressing cell line
https://www.enterprise.cam.ac.uk/reagents/fcgrllb-131r-receptor-expressing-cell-line/9 May 2022: CHO cells transfected to express human FcgRllb allotype 131R as a transmembrane protein with its native intracellular domain. -
A consultant's miscellany: Hugh Hunt's many consultancy…
https://www.enterprise.cam.ac.uk/case-studies/consultants-miscellany-hugh-hunts-many-varied-consultancy-projects/22 Mar 2022: When Cambridge Enterprise was looking to make a film about Consultancy Services, Dr Hugh Hunt, Cambridge University Reader in Engineering Dynamics and... -
BKwai raises £2.2m seed round – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/cambridge-joins-2-2m-seed-round-for-data-driven-infrastructure-and-construction-platform/8 Mar 2022: Even in new construction, it is important to ensure safe environments and understand the short- and long-term environmental impact of a site. ... The proliferation of new sensors and satellite technology has the potential to fuel a revolution in -
Human CD18 monoclonal antibody YFC 118.12
https://www.enterprise.cam.ac.uk/reagents/human-cd18-monoclonal-antibody-yfc-118-12/9 May 2022: Hybridoma cell line producing YFC118.12 antibodies raised against human CD18 which are rat monoclonal antibodies of the IgG2b isotype. -
3C Programme: Supporting the development of innovation ecosystems in…
https://www.enterprise.cam.ac.uk/case-studies/3c-programme-supporting-the-development-of-innovation-ecosystems-in-argentina/11 Apr 2022: impact of this course is enormous, and we will continue working with the University of Cambridge and the 3C Programme consortium to exploit new mechanisms for collaboration and mutual learning. -
Human CD28 monoclonal antibody YTH 913.12
https://www.enterprise.cam.ac.uk/reagents/human-cd28-monoclonal-antibody-yth-913-12/9 May 2022: Hybridoma cell line producing YTH 913.12 antibodies raised against human CD28 which are rat monoclonal antibodies of the IgG2b isotype. -
Cambridge spin-out enters $42m partnership to develop…
https://www.enterprise.cam.ac.uk/news/cambridge-spin-out-enters-42m-partnership-to-develop-future-proofed-coronavirus-vaccines/8 Mar 2022: Cambridge spin-out DIOSynVax will receive $42 million to develop a vaccine candidate to protect against existing and future variants of SARS-CoV-2. -
Human CD235a monoclonal antibody YTH 89.1
https://www.enterprise.cam.ac.uk/reagents/human-cd235a-monoclonal-antibody-yth-89-1/9 May 2022: Hybridoma cell line producing YTH 89.1 antibodies raised against human CD235a which are rat monoclonal antibodies of the IgG2b isotype. -
Versed AI case study – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/versed-ai-harnessing-artificial-intelligence-to-reveal-hidden-supply-chain-risks/11 Apr 2022: This limited visibility is an even bigger problem for SMEs. Providing an effective, new way to cut these losses offers a huge commercial opportunity. ... Mining millions of words in news articles, business reports, and social media posts, Versed AI’s -
Cambridge Enterprise joins in £18m Series B to speed adoption of…
https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-joins-in-18m-series-b-to-accelerate-adoption-of-sustainable-textile-dyeing-solution/31 May 2022: The round, led by H&M Group via investment arm H&M CO:LAB, includes existing investor, Sagana, as well as new investors Bombyx Growth Fund, PDS Ventures, Regeneration.VC and -
Human CD66acd monoclonal antibody YTH 71.3
https://www.enterprise.cam.ac.uk/reagents/human-cd66acd-monoclonal-antibody-yth-71-3/9 May 2022: Hybridoma cell line producing YTH 71.3 antibodies raised against human CD66acd which are rat monoclonal antibodies of the IgG2a isotype. -
Consultancy services case study – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/consultancy-services-a-university-lab-tests-anti-viral-materials-for-companies/11 Apr 2022: Our consultancy services team supported Department of Chemical Engineering and Biotechnology researchers in testing anti-viral materials. -
Human CD45R monoclonal antibody YTH 80.103
https://www.enterprise.cam.ac.uk/reagents/human-cd45r-monoclonal-antibody-yth-80-103/9 May 2022: Hybridoma cell line producing YTH 80.103 antibodies raised against human CD45R which are rat monoclonal antibodies of the IgG2b isotype. -
Cambridge spin-out raises £4.2m to tackle gigatonnes of emissions…
https://www.enterprise.cam.ac.uk/news/cambridge-spin-out-raises-4-2m-to-tackle-gigatonnes-of-emissions-from-highly-pollutive-cement-industry/8 Nov 2022: Carbon Re’s platform, in contrast, is already reducing emissions today, cuts the cost of production, and requires no new equipment. ... The new investment will enable product roll-out into the global cement market and expand into other energy-intensive
Search history
Recently clicked results
Recently clicked results
Your click history is empty.
Recent searches
Recent searches
Your search history is empty.